Warning! GuruFocus detected
2 Severe warning signs
with CPH.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Cipher Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA17253X1050
Compare
Compare
Traded in other countries / regions
CPH.CanadaCPHRF.USAPHE.Germany IPO Date
2004-02-25Description
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products among others. The company's geographical operational areas include Canada and the United States.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.23 | |||||
| Equity-to-Asset | 0.64 | |||||
| Debt-to-Equity | 0.41 | |||||
| Debt-to-EBITDA | 3.29 | |||||
| Interest Coverage | 32.91 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 3.51 | |||||
| Beneish M-Score | -1.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.4 | |||||
| 3-Year EBITDA Growth Rate | 16.4 | |||||
| 3-Year EPS without NRI Growth Rate | 41.2 | |||||
| 3-Year FCF Growth Rate | 17.8 | |||||
| 3-Year Book Growth Rate | 42.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 41.57 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.66 | |||||
| 9-Day RSI | 41.43 | |||||
| 14-Day RSI | 40.27 | |||||
| 3-1 Month Momentum % | -9.41 | |||||
| 6-1 Month Momentum % | -17.89 | |||||
| 12-1 Month Momentum % | 80.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2 | |||||
| Quick Ratio | 1.64 | |||||
| Cash Ratio | 0.66 | |||||
| Days Inventory | 235.93 | |||||
| Days Sales Outstanding | 102.57 | |||||
| Days Payable | 410.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 3.8 | |||||
| Shareholder Yield % | -2.24 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 80.78 | |||||
| Operating Margin % | 36.35 | |||||
| Net Margin % | 59.74 | |||||
| FCF Margin % | 49.45 | |||||
| ROE % | 18.33 | |||||
| ROA % | 15.29 | |||||
| ROIC % | 26.29 | |||||
| 3-Year ROIIC % | 48.83 | |||||
| ROC (Joel Greenblatt) % | 265.45 | |||||
| ROCE % | 10.17 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.34 | |||||
| Forward PE Ratio | 9.66 | |||||
| PE Ratio without NRI | 12.1 | |||||
| Shiller PE Ratio | 60.6 | |||||
| Price-to-Owner-Earnings | 18.89 | |||||
| PEG Ratio | 0.59 | |||||
| PS Ratio | 7.91 | |||||
| PB Ratio | 2.17 | |||||
| Price-to-Free-Cash-Flow | 15.83 | |||||
| Price-to-Operating-Cash-Flow | 15.79 | |||||
| EV-to-EBIT | 25.74 | |||||
| EV-to-EBITDA | 19.97 | |||||
| EV-to-Revenue | 9.36 | |||||
| EV-to-Forward-Revenue | 4.61 | |||||
| EV-to-FCF | 18.92 | |||||
| Price-to-GF-Value | 1.55 | |||||
| Price-to-Projected-FCF | 1.16 | |||||
| Price-to-Median-PS-Value | 2.82 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.86 | |||||
| Earnings Yield (Greenblatt) % | 3.89 | |||||
| FCF Yield % | 6.1 | |||||
| Forward Rate of Return (Yacktman) % | 19.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cipher Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 35.859 | ||
| EPS (TTM) (C$) | 0.851 | ||
| Beta | 0.7 | ||
| 3-Year Sharpe Ratio | 1.24 | ||
| 3-Year Sortino Ratio | 3.57 | ||
| Volatility % | 82.75 | ||
| 14-Day RSI | 40.27 | ||
| 14-Day ATR (C$) | 0.628491 | ||
| 20-Day SMA (C$) | 12.0715 | ||
| 12-1 Month Momentum % | 80.93 | ||
| 52-Week Range (C$) | 6.67 - 19.69 | ||
| Shares Outstanding (Mil) | 25.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cipher Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cipher Pharmaceuticals Inc Stock Events
| Event | Date | Price (C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cipher Pharmaceuticals Inc Frequently Asked Questions
What is Cipher Pharmaceuticals Inc(TSX:CPH)'s stock price today?
The current price of TSX:CPH is C$11.35. The 52 week high of TSX:CPH is C$19.69 and 52 week low is C$6.67.
When is next earnings date of Cipher Pharmaceuticals Inc(TSX:CPH)?
The next earnings date of Cipher Pharmaceuticals Inc(TSX:CPH) is 2025-03-18.
Does Cipher Pharmaceuticals Inc(TSX:CPH) pay dividends? If so, how much?
Cipher Pharmaceuticals Inc(TSX:CPH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers